Go back to News
NEWS
GA_P advises Impact Partners on Top Doctors Series B financing round
14 October, 2021
Gómez-Acebo & Pombo has advised Impact Partners on its investment in Top Doctors. The Series B financing round, led by Impact Partners and in which the Institut Català de Finances (ICF) also participated, amounted to €11.2 million.
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
¡NEW! 
PUBLICATION
4 days ago
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
4 days ago 
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026
PUBLICATION
15 Dec, 2025
Direct harm due to de facto expulsion: Article 241 of the Companies Act (Supreme Court Judgment, First Chamber, 22 October 2025)
This paper analyses the subject matter scope of application of a ‘director liability to shareholder claim’ (claim for payment of damages filed by a shareholder against a company director). Although, as a general rule, shareholders cannot claim compensation for the harm caused to their share in a company’s estate, compensation for de facto expulsions or harm to liquidating dividends may be awarded through a director liability to shareholder claim.
15 Dec, 2025
PUBLICATION
11 Dec, 2025
Do consumer associations have universal locus standi? On the subject of two orders issued by the Provincial Court of Barcelona regarding the ‘car cartel’
The universal standing of consumer associations has no legal basis and creates perverse effects.
11 Dec, 2025
PUBLICATION
09 Dec, 2025
Pharma & Healthcare No. 46
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
09 Dec, 2025
PUBLICATION
21 Nov, 2025
Compensation for loss of office ‘under market conditions’ provided for in articles of association
Judgment analyses claim filed by former CEO for non-payment of loss-of-office compensation provided for in articles of association (legal regime preceding the 2014 amendments to the Companies Act).
21 Nov, 2025
PUBLICATION
14 Nov, 2025
Automotive and Sustainable Mobility No. 28
Summary of legislative and jurisprudential developments relating to the automotive sector.
14 Nov, 2025
PUBLICATION
28 Oct, 2025
Borderline products and the precedence of medicinal product legislation
The application of the rule of precedence requires, firstly, that a given product falls within the legal definition of a medicinal product, whether it is a medicinal product by function or by presentation, and secondly, that there are doubts as to whether it also falls within the legal concept of other types of products (food supplements, cosmetics, etc.).
28 Oct, 2025